Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/1995
11/06/1995EP0687260A4 Process for the preparation of 9-desoxotaxanes
11/06/1995CA2148666A1 Substituted bicyclic heteroaroylguanidines, a process for their preparation, their use as a medicament or a diagnostic agent, and a medicament containing them
11/06/1995CA2148302A1 Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
11/04/1995CA2148324A1 Pyrrolopyrimidine derivatives having pharmacological activity
11/03/1995CA2148312A1 Modified oligonucleotides, their preparation and their use
11/02/1995WO1995029242A1 Angiostatin and method of use for inhibition of angiogenesis
11/02/1995WO1995029239A2 Compounds and methods for the stimulation and enhancement of protective immune responses and il-12 production
11/02/1995WO1995029236A2 Lymphocyte activation antigens and antibodies thereto
11/02/1995WO1995029193A2 Melanoma antigens
11/02/1995WO1995029180A1 Porphocyanine and cnc-expanded porphyrins
11/02/1995WO1995029178A1 Method for stabilizing compound dx-52-1 and lyophilized composition thereof
11/02/1995WO1995029172A1 N-morpholino-n-nitrosaminoacetonitril cyclodextrin inclusion complexes
11/02/1995WO1995028948A1 Compositions comprising dna damaging agents and p53
11/02/1995WO1995028923A1 Taxane class derivative based pharmaceutical compositions
11/02/1995EP0679718A2 Process for producing alpha-interferon
11/02/1995EP0679717A2 Soluble interferon -receptor, its preparation and use
11/02/1995EP0679657A2 Nucleosides and oligonucleotides containing 2'-ether groups
11/02/1995EP0679656A1 Improvements in platinum complexes
11/02/1995EP0679630A1 Bicyclic aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses
11/02/1995EP0679185A1 Ras associated gap proteins
11/02/1995EP0679163A1 Growth differentiation factor-3
11/02/1995EP0679160A1 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
11/02/1995EP0679156A1 Process for the preparation of 10-desacetoxybaccatin iii
11/02/1995EP0679154A1 New crystalline form of a vitamin d analogue.
11/02/1995EP0679086A1 Potentiation of temozolomide in human tumour cells
11/02/1995EP0679082A1 C10 taxane derivatives and pharmaceutical compositions
11/02/1995EP0679081A1 Pharmaceutical compositions for prevention and treatment of cancerous disease and process for their preparation
11/02/1995EP0551401B1 Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
11/02/1995EP0491956B1 Reveromycin a, production thereof, and antitumor drug and fungicide
11/02/1995CA2722364A1 Melanoma antigens
11/02/1995CA2188682A1 Method for stabilizing compound dx-52-1 and lyophilized composition thereof
11/02/1995CA2188543A1 Compounds and methods for the stimulation and enhancement of protective immune responses and il-12 production
10/1995
10/31/1995US5463181 Farnesyl: protein transferase inhibitors as anticancer agents
10/31/1995US5463083 2,5-diaryl tetrahydrothiophenes, tetrahydrofurans and 1,3-diaryl-cyclopentanes which act as platelet activating factor receptor antagonists and/or inhibitors of the enzyme 5-lipoxygenase
10/31/1995US5463063 Preparation of thalidomide; inhibitor of tumor necrosis factor
10/31/1995US5463048 Rapamycin amidino carbamates
10/31/1995US5462957 Azole derivatives, pharmaceutical compositions containing the same, and method for treating mycosis and estrogen-dependent diseases
10/31/1995US5462946 Metal-independent nitroxide or oxazolidine-1-oxyl forming compound in biologically acceptable carrier to protect biological material from oxidative stress
10/31/1995US5462939 Treating infectious diseases, septic shock, respiratory diseases, inflammatory conditions, autoimmune diseases, bone diseases
10/31/1995US5462932 Aqueous, buffered alendronate solution containing a complexing agent to prevent precipitation; bone loss prevention
10/31/1995US5462925 Transforming growth factor β2,3
10/31/1995US5462731 Administering interleukins(or derivatives)
10/28/1995CA2147798A1 Nucleosides and oligonucleotides having 2'-ether groups
10/26/1995WO1995028493A1 Aav-mediated delivery of dna to cells of the nervous system
10/26/1995WO1995028488A1 NON-SPLICING VARIANTS OF gp350/220
10/26/1995WO1995028483A1 Cell-cycle regulatory proteins, and uses related thereto
10/26/1995WO1995028422A1 Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
10/26/1995WO1995028407A1 Lobaplatinum trihydrate
10/26/1995WO1995028406A1 Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them
10/26/1995WO1995028169A1 Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
10/26/1995CA2188180A1 Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
10/26/1995CA2186639A1 Cell-cycle regulatory proteins, and uses related thereto
10/25/1995EP0678744A2 Method for detecting urinary tumor associated antigens
10/25/1995EP0678298A2 Use of 4-(2-formyl-3-hydroxyphenoxymethyl)benzoic acid as immopotentiatory agent
10/25/1995EP0678122A1 Recombinant anti-vla4 antibody molecules
10/25/1995EP0678101A1 Growth differentiation factor-9
10/25/1995EP0678087A1 Compounds having selective activity for retinoid x receptors, and means for modulation of processes mediated by retinoid x receptors
10/25/1995EP0678086A1 Compounds having selectivity for retinoid x receptors
10/25/1995EP0678034A1 Inducing cytotoxic t lymphocyte responses
10/25/1995EP0678025A1 Transdermal treatment of cancer with water-insoluble s-camptothecin of the closed lactone ring form
10/25/1995CN1110563A Injection containing ginseng and astragalus root components
10/25/1995CN1030141C Process for proaartion of 4'-demethylepipodophyllotixin glucoside 4'-phosphates
10/24/1995US5461176 Reacting alanine methyl ester with oxalyl chloride, treating with ammonia in methanol, reducing amides with diborane in tetrahydrofuran, neutralizing with sodium ethoxide to yield free amine
10/24/1995US5461078 Anti-cancer compounds
10/24/1995US5461067 For HIV infections
10/24/1995US5461036 Treating colon, gastric, esophageal cancer
10/24/1995CA1337424C Antitumour compounds from marine sponge of the genus dercitus
10/24/1995CA1337420C (substituted aralkyl) heterocyclic compounds
10/24/1995CA1337408C Soluble phosphorylated glucan
10/19/1995WO1995027793A1 DNA ENCODING PRECURSOR OF INTERLEUKIN-1β CONVERTING ENZYME-RELATED CYSTEINE PROTEINASE II (ICErel-II)
10/19/1995WO1995027792A1 DNA ENCODING PRECURSOR OF INTERLEUKIN-1β CONVERTING ENZYME-RELATED CYSTEINE PROTEINASE III (ICErel-III)
10/19/1995WO1995027784A1 Cisplatin resistance gene and uses therefor
10/19/1995WO1995027731A1 Compound ge3
10/19/1995WO1995027723A1 Receptor modulating agents and methods relating thereto
10/19/1995WO1995027712A1 Novel spiro[indole-pyrrolidine] derivatives as melatoninergic agonists, method for preparing same and use thereof as a drug
10/19/1995WO1995027699A1 Aminostilbazole derivative and medicine
10/19/1995WO1995027483A1 Carotenoid agent for inhibiting the conversion of epithelial cells to tumours
10/19/1995WO1995027480A1 Heme-bearing microparticles for targeted delivery of drugs
10/19/1995WO1995024481A3 Humanized monoclonal antibodies against human interleukin-4
10/19/1995CA2187367A1 Carotenoid agent for inhibiting the conversion of epithelial cells to tumours
10/19/1995CA2187312A1 Heme-bearing microparticles for targeted delivery of drugs
10/19/1995CA2164618A1 Compound ge3
10/19/1995CA2163526A1 Cisplatin resistance gene and uses therefor
10/18/1995EP0677104A1 Activin receptor-like kinases, proteins having serine threonine kinase domains and their use
10/18/1995EP0677063A1 A NEW CLASS OF RPTPases: THEIR STRUCTURAL DOMAINS AND LIGANDS
10/18/1995EP0677060A1 Peptide inhibitors of cell adhesion
10/18/1995CN1110323A Novel polypeptides and DNAS encoding them
10/18/1995CN1110280A Targeted forms of methyltrithio antitumor agents
10/17/1995US5459248 Process of preparing etoposide phosphate and etoposide
10/17/1995US5459159 Anticarcinogenic/antitumor agents; allowing accumulation in abnormal cells, irradiation with light of specified wavelength
10/17/1995US5459141 Compounds 31668P and 31668U, a process for their production and their use
10/17/1995US5458878 P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
10/17/1995CA1337330C Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinaceous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
10/12/1995WO1995027202A1 Screening method using the rzr receptor family
10/12/1995WO1995027066A2 Dna encoding ubiquitin conjugating enzymes
10/12/1995WO1995027044A1 ALPHAVIRUS cDNA VECTORS
10/12/1995WO1995026986A1 Monoclonal antibody to oncofetal protein for treating and detecting cancer
10/12/1995WO1995026981A2 Peptides having farnesyl transferase inhibiting properties and strain of genus streptomyces for producing same
10/12/1995WO1995026972A1 Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
10/12/1995WO1995026968A1 Trinuclear cationic platinum complexes having antitumour activity and pharmaceutical compositions containing them
1 ... 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 ... 2211